Close

Five Prime (FPRX) Announces FDA Orphan Drug Designation for FPA144 to Treat Gastric Cancer

July 5, 2016 9:29 AM EDT Send to a Friend
Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login